Title of the cohort

The Vallecas Project – Early detection of Alzheimer’s Disease

Acronym for cohort


Name of Principal Investigator
First name Jose L.
Last nameDobato-Ayuso
Address of institution where award is held
InstitutionResearch Unit, Alzheimer Center Reina Sofia Foundation
Street AddressCalle de Valderrebollo, 5




Contact email
Funding source

Reina Sofia Foundation
Alzheimer Disease Association (AFAL)
CIEN Foundation

1. The cohort includes, or expects to include, incidence of the following conditions
  • Alzheimer’s disease and other dementias
When studies on the above condition(s) are expected to become possible

Already possible

2a. Stated aim of the cohort

To obtain an algorithm of probability (based on historical, clinical, neuroimaging, and biological data) for calculation of the dementia/AD risk in a 5-year horizon. Pilot study done. Launching: June 2011.

2b. Features distinguishing this cohort from other population cohorts

To identify, in population 70-85 y., the individuals in risk for dementia in few years, based on clinical data, MRI, and blood, using data mining. Aimed at finding a probability, not a marker.

3a. i) Number of publications that involve use of cohort to date
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort

This integrator study will provide socio-demographic and clinical data that combined with biological data from blood and MRI will allow to calculate the risk for development of dementia in a few years span. For clinical trials with disease modifiers, this population will be essential (and preferential for treatment).

4a. Study criteria: age range of participants at recruitment
Age in years from:70
To (‘until death’ if applicable):85
4b. Study criteria: inclusion criteria

Population 70 to 85 years old, without dementia ot other impairment of mental function interfering with daily life. Subjective memory complaints and mild cognitive impairment are suitable for inclusion.

4c. Study criteria: exclusion criteria

Dementia (any degree) at baseline, or other disorder of mental functions interfering with assessments. Existence of a severe disease impeding long-term follow-up.

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

MMSE, Pfeffer’s FAQ, Visuospatial tests, CDR <1

6b. Additional measures for participants with a clinical disorder

Set Test, Buschke’s Verbal Learning test, Symbol-digit test, Apathy inventory, motor evaluation.
MRI 3T – Volumetry,
Blood- APOE, susceptiblity genes, biochemical determinations

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)


7. Study design
  • Prospective cohort
  • Longitudinal
8. Cases matched by
  • Age
  • Cognitive function
9a. Does the study include a specialised subset of control participants


9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date


10a. ii) Data collection end date


10a iii) Data collection for this study is
  • At the planning stage
10b. Plans to continue the cohort study beyond the current projected end date
11. Data collected
  • Only through the study
12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database
Yes/No% available
Data summarised in database
Database is web-based
Database on spreadsheet Yes
Database is on paper
Other (specify)
Language used:


13b. Format and availability of data held as individual records
Yes/No% available
Data held as individual records
Data is web-based
Data held on computer based recordsYes
Data held on cards
Other (specify)
Language used:


14a. Are data available to other groups


14b. Access policy/mechanisms for access if data are available to other groups
15. Data sharing policy specified as a condition of use

No policy exists

16a. Are tissues/samples/DNA available to other groups


16b. i) Description of available tissues/samples/DNA
  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA
  • Post-mortem donors: brain
16b. ii) Form available tissues/samples/DNA are supplied in
  • Primary samples: Supplied fresh
  • Primary Samples: Stabilised samples (frozen or fixed)
  • Secondary samples: derivatives of primary samples
  • Secondary samples: plasma
  • Secondary samples: DNA
  • Secondary samples: RNA
  • Secondary samples: protein extracts
  • Secondary samples: cell lines derived from primary samples
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data


17. Is information on biological characteristics available to other groups
  • No

    Types: Population Cohorts
    Member States: Spain
    Diseases: Alzheimer's disease & other dementias
    Years: N/A
    Database Categories: N/A
    Database Tags: N/A

    Export as PDF